AI assistant
Sun Pharmaceutical Industries Ltd. Capital/Financing Update 2021
59215_rns_2021-11-11_b051f8be-5727-41c9-9748-5a60a958b7bb.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1 , Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com
November 11, 2021
National Stock Exchange of India Limited, Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Sandra Kurla Complex, Sandra (East), Mumbai- 400 051
Scrip Symbol: SUNPHARMA
BSE Limited, Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001
Scrip Code: 524715
Sub: Press Release
Dear Sir I Madam,
Please find enclosed herewith our Press Release relating to Sun Pharma gearing up to introduce Merck Sharpe Dohme (MSD) and Ridgeback's molnupiravir under the brand name Molxvir® in India, which we shall be r.eleasing after sending this letter to you.
This is for your information and dissemination.
Thanking you,
Yours faithfully, For Sun Pharmaceutical Industries Limited
Ashok I. Bhuta Compliance Officer Enclosed: As above
Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com
FOR IMMEDIATE RELEASE
Sun Pharma geared to introduce Molnupiravir, licensed from MSD and Ridgeback, under the brand name Molxvir® in India
Mumbai, November 11, 2021: Sun Pharmaceutical Industries Limited. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today said that it is gearing up to introduce Merck Sharpe Dohme (MSD) and Ridgeback's molnupiravir under the brand name Molxvir® in India. The Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COVID-19 in adults in India. Earlier this year, Sun Pharma had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply molnupiravir in India and to over 100 low and middle-income countries (LMICs).
Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID -19 in adults. It is under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA).
Kirti Ganorkar, CEO of India Business, Sun Pharma said, "The recent authorisation of molnupiravir, licensed from MSD and Ridgeback, by the UK regulator is a positive step. In line with our consistent efforts to accelerate access to new drugs for COVID-19 treatment, we are gearing up to make Molxvir® available to patients and healthcare providers across India at an economical price post approval by DCGI. Molxvir® will be manufactured at one of our plants in India and we have enough capacity to meet the demand."
In the Phase 3 trial by Merck, Molnupiravir significantly reduced the risk of hospitalization or death by approximately 50% in a planned interim analysis of the MOVe-OUT trial in at risk, nonhospitalized adult patients with mild-to-moderate COVID-19. Additionally, based on the participants with available viral sequencing data (approximately 40% of participants), molnupiravir demonstrated consistent efficacy across viral variants like Gamma, Delta, and Mu.
Molxvir® is a registered trade mark of Sun Pharma.
Disclaimer:
Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.
Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com
About Sun Pharmaceutical Industries Limited. (CIN - L24230GJ1993PLC019050):
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6-7% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live.
Contacts:
| Investors: | Media: | ||
|---|---|---|---|
| Nimish Desai | Gaurav Chugh | ||
| Tel | +91 22 4324 4324, Xtn 2778 | Tel | +91 22 4324 4324, Xtn 5373 |
| Tel Direct | +91 22 4324 2778 | Tel Direct | +91 22 4324 5373 |
| Mobile | +91-98203 30182 | Mobile | +91 98104 71414 |
| E mail | [email protected] | E mail | [email protected] |